↑ Rising
Business
Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail
Novartis absorbs a $1.9 billion trial loss yet lifts guidance, leaving investors to weigh confidence in the Avidity deal.
Del-Desiran
2 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Del-Desiran
This hub groups 2 separate news trends connected to Del-Desiran, spanning September 10, 2026 through October 28, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 13 article observations and 13 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
Novartis faces activist pressure as a major shareholder demands board changes after a costly drug trial failure.